Compare UTF & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | HAE |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2004 | 1996 |
| Metric | UTF | HAE |
|---|---|---|
| Price | $26.98 | $54.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $84.13 |
| AVG Volume (30 Days) | 295.3K | ★ 631.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.54 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | ★ N/A | $22.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.42 | $47.32 |
| 52 Week High | $27.35 | $87.32 |
| Indicator | UTF | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 42.10 |
| Support Level | $26.65 | $54.92 |
| Resistance Level | $27.17 | $56.64 |
| Average True Range (ATR) | 0.34 | 2.73 |
| MACD | 0.04 | -0.60 |
| Stochastic Oscillator | 74.07 | 41.01 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.